Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Targeting tumor cells with chemotherapeutic agents conjugated to Anti-matriptase antibodies by in vivo cleavable linking moieties

a technology of in vivo cleavage and binding moieties, which is applied in the field of new immunoconjugates comprising an anticancer agent and a monoclonal antibody, can solve the problems of limiting the clinical value of a stand-alone compound, poor outcome for breast cancer patients, and high cytotoxicity, and achieves less toxicity

Inactive Publication Date: 2019-05-23
RUTGERS THE STATE UNIV +1
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides an anti-matriptase antibody that can be used to target cancer cells. This antibody is conjugated to a potent anticancer drug, making it selective and less toxic towards normal tissues. The levels of matriptase mRNA have been found in various types of cancer, making this immunoconjugate useful for treating multiple types of cancer.

Problems solved by technology

High levels of Met combined with overexpression of matriptase are associated with a poor outcome for patients with breast cancer.
MMAE is a potent antimitotic compound but it exhibits high levels of cytotoxicity when administered alone, limiting its clinical value as a stand-alone compound.
Like MMAE, MMAF exhibits high levels of cytotoxicity when administered alone.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Targeting tumor cells with chemotherapeutic agents conjugated to Anti-matriptase antibodies by in vivo cleavable linking moieties
  • Targeting tumor cells with chemotherapeutic agents conjugated to Anti-matriptase antibodies by in vivo cleavable linking moieties
  • Targeting tumor cells with chemotherapeutic agents conjugated to Anti-matriptase antibodies by in vivo cleavable linking moieties

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0186]Expression of Matriptase in Multiple Myeloma and B-Cell Lymphoma Cells

[0187]A panel of 24 cell lines of human hematopoietic malignancies was analyzed by Western blotting for matriptase as well as its endogenous inhibitor HGF activator inhibitor-1 or HAI-1 (FIG. 1). Cell lysates were prepared from 24 hematopoietic cancer cells (lanes 2-14) and T-47D breast cancer cells (lane 1). Equal amounts of proteins were resolved by SDS-PAGE. Levels of matriptase and HAI-1 were assessed by immunoblot analysesusing an anti-matriptase mAb and anti-HAI-1 mAb as indicated (FIGS. 1A and 1B).

[0188]Matriptase was expressed in the majority of the B-cell lymphomas as well as in multiple myeloma cells, indicating that the protease is an important marker for these cancers. In contrast, HAI-1 levels in lymphoma and myeloma appear to be much lower than those in carcinomas, and HAI-1 expression is often lost in highly aggressive lymphomas (Table 1).

[0189]To further verify the expression of matriptase in...

example 2

[0191]Preparation of DOX-Immunoconjugate

[0192]Monoclonal antibodies against matriptase (M24 or M69, obtained from C Y Lin, University of Maryland, Baltimore, Md.; Lin C. Y., et al., J. Biol. Chem., 1999, 274 (26):18237-18242; Chen, Y. W., et al. J. Biol. Chem., 2010, 285 (41):31755-31762) was conjugated to DOX (Sigma) by using Protein-Protein Coupling kit (Invitrogen) according to the manufacture's instruction with some minor modification. Briefly, DOX was reacted with crosslinker SMCC (succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate) at a molar ratio (MR) between 1:3 and 1:1.5 (DOX:SMCC) for 1 hour at room temperature with constant stiffing. About 200 mg M24 mAb was reacted with SPDP (Succinimidyl 3-(2-pyridyldithio)-propionate) for 1 hour at room temperature followed by exchange of phosphate buffer using Centrifugal Filter Device (Ultrafree, Millipore). Alternatively, the mAb can be separated from free SPDP by gel filtration with Sephadex G50. DOX maleimide derivative ...

example 3

Cytotoxicity of M24-DOX Toward Multiple Myeloma Cells

[0195]To assess the cytotoxic effect of the immunoconjugate, MM cells were treated with the conjugated DOX at various concentrations for 48 hours. The immunoconjugate inhibited cell proliferation in a dose-dependent manner. The EC50 of the immunoconjugate was 5 μg / ml (protein). This cytotoxic effect was also observed with treatment of free DOX at 200 nM. As the concentration of M24-DOX at 5 μg / ml is equivalent to 250 nM of free DOX based on the intensity of fluorescence, the potency of the conjugated DOX is therefore similar to the free drug. Exposure of the cells to unmodified antibody had no effect on cell growth, demonstrating that the M24-DOX induced cytotoxic effect is mediated through DOX activity. Two other MM cell lines including OPM-2 and RPMI-8226 were also tested for the cytotoxic activity of M24-DOX as shown in FIG. 2 where MM cells (1×105 / well) in 24-well plates were treated with or without M24-DOX at varying concentr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
weightaaaaaaaaaa
weightaaaaaaaaaa
Login to View More

Abstract

The present invention relates to anti-matriptase antibodies and immunoconjugates of anti-matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising an anti-matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase. In addition, administration of an anti-matriptase antibody or immunoconjugates of an anti-matriptase antibody and a cytotoxic agent in combination with administration of an immunomodulatory agent, such as thalidomide or an analog thereof, provides a more effective treatment of these cancers.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]The present application claims priority to U.S. patent application Ser. No. 15 / 075,008, which is a continuation-in-part under 35 U.S.C. § 120 of U.S. patent application Ser. No. 13 / 510,801, filed May 18, 2012, which is a National Stage Entry of PCT / US10 / 57235, filed Nov. 18, 2010, which in turn claims priority under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 61 / 293,030, filed Jan. 7, 2010, and U.S. Provisional Application No. 61 / 262,373, filed Nov. 18, 2009. All of the foregoing references are hereby incorporated by reference in their entirety.FIELD OF THE INVENTION[0002]The present invention relates to new immunoconjugates comprising an anticancer agent and a monoclonal antibody and use of such immunoconjugates for killing or inhibiting the growth of matriptase expressing cancer cells, including but not limited to hematological malignancies and epithelial cancers, such as those of multiple myeloma and breast cancers. Thus, th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K47/68C07K16/40A61K31/4439A61K31/40A61K47/60A61P35/00
CPCA61K47/6871A61K47/6803C07K16/40A61K31/4439A61K31/40A61K47/60A61P35/00C07K16/3015C07K16/3038C07K16/3061A61K2039/505A61K47/65A61K47/6809A61K47/6811C07K16/30C07K2317/73A61K47/68031A61K39/39558
Inventor LIN, SIANG-YOBERTINO, JOSEPH R.LIN, CHEN-YONGSZEKELY, ZOLTAN
Owner RUTGERS THE STATE UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com